Reports

Drug name	NICE TAs	Comments
Omalizumab	TA339 - Omalizumab for previously treated chronic spontaneous urticaria TA278 - Omalizumab for treating severe persistent allergic asthma	Hospital only
Omalizumab#13.5	TA339 - Omalizumab for previously treated chronic spontaneous urticaria
Osimertinib	TA416 - Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer TA653 - Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer TA654 - Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer TA761 - Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection
Osimertinib	NICE TA Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer
Oxaliplatin injection	TA100 - Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes' C) colon cancer TA33 - The clinical effectiveness and cost effectiveness of irinotecan, oxaliplatin and raltitrexed for colorectal cancer TA212 - Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer
Ozanimod (Zeposia®)	TA828 - Ozanimod for treating moderately to severely active ulcerative colitis
Ozanimod (Zeposia®)	TA828: Ozanimod for treating moderately to severely active ulcerative colitis
Paclitaxel	TA55 - Guidance on the use of paclitaxel in the treatment of ovarian cancer TA91 - Paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan for second-line or subsequent treatment of advanced ovarian cancer
Paclitaxel injection	TA214 - Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer TA284 - Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer	Negative TA
Palbociclib (Ibrance®)	TA495 - Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer TA619 - Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer TA836: Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
Next page
Last page

University Hospitals Birmingham NHS Foundation Trust

Medicines Formulary

Reports